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Introduction
 
Hereditary hemochromatosis (HH) is a disorder characterized by enhanced intestinal 
absorption of dietary iron. Without therapeutic intervention, iron overload leads to multiple 
organ damage such as liver cirrhosis, cardiomyopathy, diabetes, arthritis, hypogonadism and 
skin pigmentation. The most common intervention is therapeutic phlebotomy, which consists of 
regular blood withdrawal (usually 400-500 mL per session) until serum ferritin is controlled(1-5).
HFE mutations are, by far, the most common genetic abnormality involved in HH, 
especially the genotypes: homozygosity for p.Cys282Tyr or the p.Cys282Tyr/p.His63Asp 
compound heterozygosity. However, since the causal association between HFE mutations 
and HH was discovered in 1996, it became evident that there are cases of HH that cannot be 
explained by HFE gene mutations. As a consequence, cases of HH that are not associated with 
HFE mutations are collectively referred to as non-HFE hemochromatosis; these comprise 
mutations in the genes that encode hemojuvelin (HJV), hepcidin (HAMP), transferrin receptor 
2 (TFR2) and ferroportin (SLC40A1)(6-8). Cases of HH due to HJV or HAMP mutations are 
denominated type 2 HH; those related to TFR2 mutations are named type 3 HH; and cases 
associated with SLC40A1 mutations, which can be significantly different from classic cases of 
HH, receive the denomination of type 4 HH or “ferroportin disease”.
Considering that the group of non-HFE hemochromatosis has many peculiarities, the 
aim of this review is to explore molecular, clinical and management aspects of non-HFE 
hemochromatosis.
 
Juvenile Hemochromatosis or Type 2 hereditary hemochromatosis
Juvenile hemochromatosis (JH), also classified as type 2, is a rare autosomal 
recessive disorder of iron overload that leads to organ damage before the age of 30. JH is 
characterized by severe iron overload usually associated with liver damage, cardiomyopathy 
and/or hypogonadotrophic hypogonadism. Hypogonadism is the main symptom at disease 
presentation, and the course of symptoms is more rapid and severe than classic HFE 
hemochromatosis (type 1)(9). Men and women are equally affected. Typically, patients with 
JH die prematurely of cardiovascular causes before reaching their fourth decade of life. JH 
is subdivided in types 2A (OMIM 602390) and 2B (OMIM 613313), which are caused by 
mutations in the HJV and HAMP genes, respectively(10-12).
Both types 2A and 2B HH are associated, in their final pathophysiology, with hepcidin 
regulation. Hepcidin is a hormone produced by hepatocytes, which plays an important role in 
iron homeostasis by regulating its absorption and release in the enterocytes and macrophages(13).
The HJV (OMIM 608374) gene is constituted by 4 exons located in chromosome 1. It was 
identified in 2004 and encodes a protein called hemojuvelin(10). This protein is critical for iron 
homeostasis regulation and for hepcidin expression in response to iron. In this scope, patients 
with type 2A JH and HJV knockout mice models demonstrate low hepcidin levels suggesting 
that hemojuvelin is involved in hepcidin synthesis(14). Several HJV mutations associated with JH 
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Table 1 - Characteristics according to non-HFE hemochromatosis(19, 59-61)
Type of HH
Gene 
(MIM 
number)
Inheritance Gene product function
Main clinical 
manifestations Main mutations
2A HJV(608374)  AR
Involved
in hepcidin 
synthesis, BMP
co-receptor
Types 2: earlier onset,
<30 years old. 
Hypogonadism and 
cardiomyopathy more 
prevalent
p.Arg54del, p.Cys80Arg, 
p.Ser85Pro, p.Gly99Arg, 
p.Gly99Val, p.Leu101Pro, 
p.Gly116del, p.Cys119Phe, 
p.Ile222Asn, p.Arg131fs, 
p.Asp149fs, p.Leu165del, 
p.Ala168Asp, p.Phe170Ser, 
p.Asp172Glu, p.Arg176Cys, 
p.Trp191Cys, p.Asn196Lys, 
p.Ser205Arg, p.Ile222Asn, 
p.Lys234del, p.Asp249His, 
p.Gly250Val, p.Asn269fs, 
p.Ile281Thr, p.Arg288Trp, 
p.Cys321Trp, p.Cys321del, 
p.Arg326del, p.Ser328fs, 
p.Cys361fs, p.Arg385del
2B HAMP(606464) AR
Downregulation 
of iron efflux from 
enterocytes
Same as above
p.Met31fs, p.Met50fs, p.Arg56del, 
p.Arg59Gly, p.Cys70Arg, 
p.Gly71Asp, p.Cys78Thr
3 TFR2(604720) AR
Involved in 
hepcidin synthesis,
interaction with
transferrin
As for HFE-related HH: 
Arthropathy, skin
pigmentation, liver 
damage, diabetes, 
endocrine dysfunction, 
cardiomyopathy, 
hypogonadism
p.His33Asn, p.Glu60del, 
p.Arg105del, p.Met172Lys, 
p.Tyr250del, p.Gln317del, 
p.Arg396del, p.Ala444Thr, 
p.Arg455Gln, p.Arg481His, 
p.Leu490Arg, p.Val561del, 
p.Gln690Pro, p.Gly792Arg
4 SLC40A1 (604653) AD
Duodenal iron 
export
Lower tolerance to 
phlebotomies and may 
have anemia
p.His32Arg, p.Tyr64Asn, 
p.Val72Asp, p.Ala77Asp, 
p.Gly80Val, p.Arg88Thr, 
p.Asn144His, p.Asp157Gly, 
p.Asp157Asn, p.Val162del, 
p.Asn174Ile, p.Arg178Gly, 
p.Ile180Thr, p.Asp181Val, 
p.Gln182His, p.Asn185Asp, 
p.Gln248His, p.Gly267Asp, 
p.Gly323Val, p.Cys326Ser, 
p.Cys326Tyr, p.Gly330del, 
p.Ser338Arg, p.Arg489Ser, 
p.Gly490Asp, p.Gly490Val
MIM = Mendelian inheritance in man; HJV= encodes hemojuvelin; HAMP= encodes hepcidin; TFR2= encodes transferrin receptor 2; 
SLC40A1= encodes ferroportin; BMP = bone morphogenetic protein, AR = autosomal recessive; AD = autosomal dominant
have been described in the literature (Table 1). However, HJVp.
Gly320Val is the most important mutation and has been reported in 
JH patients in several different populations around the world(10,15-19).
The HAMP (OMIM 606464) gene directly encodes 
hepcidin which is produced by hepatocytes and plays a role 
in iron absorption related to ferroportin degradation of the 
enterocytes(12,20). Mutations in the HAMP gene, which is 
constituted by 3 exons and located in chromosome 19, are a very 
rare cause of JH. Since its description, some mutations have 
already been described (Table 1)(12,19,21,22). 
Type 3 hereditary hemochromatosis
 
Type 3 HH (OMIM 604250) is an autosomal recessive 
disease caused by mutations in the TFR2 gene. The first 
description of this disease, in two Sicilian families, dates back to 
2000 and is the first diagnosis of hemochromatosis attributed to a 
gene mutation other than HFE(23).
Type 3 HH leads to an iron overload similar to HFE 
hemochromatosis, and, consequently, may present with abnormal 
liver function, diabetes, hypogonadism, cardiomyopathy and 
arthritis(24). The typical onset is during adulthood, but inheritance 
of both TFR2 and HFE mutations are known to lead to an earlier 
onset of the disease(25).
TFR2 gene (OMIM 604720) is constituted by 18 exons and 
encodes the transferrin receptor 2 protein (TFR2). Different to 
TFR1, TFR2 expression is restricted almost entirely to the liver(26). 
Rather than only being involved with the uptake of transferrin-
bound iron by hepatocytes, TFR2 is a sensor of iron levels and is 
also involved in hepcidin synthesis(23,27-29).
Type 3 HH is a rare condition and usually presents with 
decreased hepcidin levels. Known TFR2 mutations are shown in 
Table 1(19,23,30-34).
 
Type 4 hereditary hemochromatosis or ferroportin disease
Type 4 HH (OMIM 606069), or ferroportin disease, is 
an autosomal dominant disease that has been associated with 
mutations in the SLC40A1 gene since 2001 (Table 1)(19,30,35-40). The 
SLC40A1 (OMIM 604353) gene, constituted by 8 exons, encodes 
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a protein named ferroportin, which is a transmembrane iron 
transporter expressed in macrophages, enterocytes, hepatocytes 
and syncytiotrophoblasts(35,41). Ferroportin is responsible for iron 
transportation across the enterocyte surface and for iron recycling 
in the reticuloendothelial system(26). It is known that hepcidin 
binds to ferroportin, promoting its internalization and degradation 
leading to a decrease in iron absorption and, consequently, to a 
reduction in serum iron. Even ferroportin expression on the cell 
surface can be regulated by hepcidin(20).
Patients with ferroportin disease, differently from HFE 
HH, typically present with low to normal transferrin saturation 
(TS) and iron overload within macrophages, mainly from the 
liver, spleen and bone marrow. In these cases, a mild iron-
deficient anemia may be present at the initial stage leading to a 
reduced tolerance to therapeutic phlebotomy(40-42). However, it is 
also known that some cases of ferroportin disease may present 
phenotypically very similar to HFE HH with high TS and an iron 
overload predominantly in hepatocytes(43,44). Regarding these two 
possible phenotypes of the disease, it has recently been shown 
that this difference may be due to the patterns of SLC40A1 
mutations. While the most common phenotype is related to a loss 
of iron exporting activity of ferroportin, the latter (more similar 
to HFE HH), may be associated with mutations that lead to a 
hepcidin-resistant ferroportin(41).
 
Diagnosis of non-HFE hemochromatosis
Similarly to HFE HH, initial suspicions of non-HFE HH 
are related to abnormalities in iron biochemical assays. Typically, 
patients present with increased levels of TS (≥ 45%), which is 
the earliest phenotypic biochemical indication of HH, and raised 
serum ferritin. It is important to point out that ferritin is an acute 
phase reactant and, as a consequence, can be elevated in many 
situations other than HH; other possible causes must be discarded 
before proceeding with the HH investigation process(45-47). 
However, hyperferritinemia remains one of the most common 
signs and is identified from either a systematic biochemical 
workout or the diagnostic procedure with a large number of 
opening symptoms such as fatigue, joint pain, jaundice, skin 
pigmentation, neurological signs, impotence, diabetes, heart 
disease and even anemia.
A four-step strategy can be proposed to progressively narrow 
the field of putative causes of hyperferritinemia(48,49).
Step 1) Rule out an acquired cause of hyperferritinemia 
unrelated to significant iron overload (IOL). Non-hereditary 
causes of hyperferritinemia are numerous and much more 
prevalent than hereditary abnormalities of iron metabolism. 
Thus, neglecting this step usually results in unnecessary genetic 
testing. The main causes of non-IOL related hyperferritinemia 
are: inflammatory syndrome, cell necrosis, chronic alcohol 
consumption and metabolic syndrome. Personal and family 
history, clinical examination including biometric evaluation 
(body mass index, waist circumference and blood pressure), iron 
parameters (serum ferritin and TS) and some simple biochemical 
tests (C-reactive protein, hemoglobin, alanine aminotransferase 
and aspartate aminotransferase) in most cases, allow the diagnosis 
of acquired hyperferritinemia.
Step 2) Confirm IOL and rule out acquired causes. The 
determination of TS is necessary at an early stage in the diagnostic 
algorithm. However, due to the test variability throughout a day 
and depending on technical procedures, any increase in TS must 
be verified. Repeatedly high TS levels usually denote IOL. It 
should be noted that a high TS is a particularly valuable indicator 
for the presence of a HFE mutation. The main causes of acquired 
IOL are: chronic anemia (thalassemia major, myelodysplastic 
syndrome, sideroblastic anemia, chronic hemolysis), excessive 
iron supplementation (oral or parenteral iron, transfusions), 
porphyria cutanea tarda, chronic liver disease (alcoholic, viral or 
metabolic), end stage chronic liver disease.
Step 3) As serum ferritin may be increased due to a variety 
of causes unrelated to IOL, the third step is to assess hepatic iron 
stores directly. Magnetic resonance imaging is then necessary to 
authenticate high hepatic iron content. Liver biopsy is indicated if 
it can supply information that imaging or blood tests cannot and 
that will help patient management.
Step 4) Confirm the hereditary character of IOL and the 
precise gene(s) involved. The term of hereditary IOL is restricted 
to IOL conditions related to primary (genetic) abnormalities of 
iron metabolism. However in clinical practice, once hepatic IOL 
has been proven, phlebotomy must be initiated rapidly without 
waiting for sequencing results. Quantification of the total iron 
removed by phlebotomies may serve as an additional argument 
for retrospective evaluation of the extent of iron accumulation.
Molecular assaying of HFE mutations should be performed 
only in cases with increased biochemical values and in those 
with familial history of HFE HH(50). Initially, the two main HFE 
mutations (p.Cys282Tyr and p.His63Asp) should be tested and, 
in their absence, non-HFE HH should be suspected. Hence, when 
there is iron overload in an under 30-year-old patient with cardiac 
or endocrine manifestations, a diagnosis of type 2 HH needs to 
be considered. Thus, the evaluation of the p.Gly320Val mutation 
in the HJV gene must be the molecular test of choice(5,51). If the 
result is negative, sequencing should be considered to evaluate 
the HJV and HAMP genes (Figures 1 & 2).
In addition, mutations in the TFR2 and SLC40A1 genes 
are rare, but they have been reported in child, adolescent, and 
adult cases. Considering the current advances in sequencing, it 
is recommended that, ideally, these genes should be evaluated to 
investigate non-HFE HH in patients with negative results for the 
HFE mutation but with clinical manifestations of primary iron 
overload (Figures 1 & 2). Considering that direct sequencing is 
yet not widely available, usually this last approach is reserved for 
scientific studies and in the investigation of refractory cases(5,7,52-54).
 
Therapeutic management
Therapeutic management of non-HFE hemochromatosis, 
except for ferroportin disease, is similar to that of HFE HH. 
Venesection (phlebotomy) is the cornerstone of therapy; its 
goal is to reduce ferritin to low normal range, usually 50-100 
µg/L(52). This therapeutic strategy is associated with significant 
improvement in liver and skin manifestations of the disease 
and it is also related to higher survival(55). On the other hand, 
extrahepatic manifestations such as hypogonadism, arthropathy 
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µg/L (through weekly or two-weekly phlebotomy sessions with 
withdrawal of 400-500 mL of total blood), maintenance sessions 
should be initiated, aiming to keep ferritin levels between 50 and 
100 µg/L. All patients should be advised against the abusive use 
of alcohol and vitamin C during the treatment.
Patients with ferroportin disease are usually intolerant of 
conventional phlebotomies. In these cases, a less aggressive 
phlebotomy regimen should be attempted, and adjunctive therapy 
with erythropoietin may be beneficial(11). Also, in cases of intense 
side effects with phlebotomy, such as in patients with anemia or 
heart failure, the use of oral iron chelators such as deferasirox 
may be a safe therapeutic option(1-5).
Erythrocytapheresis has also been mentioned as a possible 
therapeutic option for patients with HH, but its use is rarely seen 
in clinical practice(50).
 
Conclusions
Advances in the understanding of non-HFE HH have been 
obtained over the years including: association of HJV and HAMP 
mutations with the juvenile form, several pathogenic mutations 
associated with non-HFE HH, hepcidin as an iron hormone and its 
relationship with HFE protein, comprehension of the molecules 
involved in iron homeostasis, new techniques for the laboratorial 
evaluation, and increased knowledge about HH therapeutic 
management. Nonetheless, there are still unclear points to be 
explored in the non-HFE HH context, such as the better approach 
to the molecular investigation and therapeutic management.
In this scope, considering the rapid development of molecular 
techniques, which are becoming faster, more precise and 
HJV  p.Gly320Val
Increased TS and/or SF *
< 30 years old and cardiac or endocrine manifestations
Negative results for the HFE gene, specially for the p.Cys282Tyr and p.His63Asp mutations
HJV  sequencing
+
+
-
-
Type 2A JH HAMP
sequencing
Type 2B JH Types 3 and 4 HH
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Figure 1 - Representation of molecular investigation strategy for non-HFE hereditary hemochromatosis.
* Recommendations report TS > 45%, SF > 200 µg/L in females and > 300 µg/L in males; or in advanced stages: TS > 50% in females and TS > 60% in males, 
in the absence of secondary causes(50,62)
** Some patients with primary iron overload may not present mutations during this genetic approach. Very rare mutations in other genes may be involved(7,63)
TS = transferrin saturation; SF = serum ferritin; JH = juvenile hemochromatosis. + means positive result and - means negative result
Figure 2 - Representation of the hereditary hemochromatosis types 
according to involved genes and phenotypes.
and diabetes are irreversible irrespective of treatment(52). The 
benefits of phlebotomy for HH have been demonstrated in cohort 
studies, but not in clinical randomized trials. However, it is 
known that survival of HH patients subjected to phlebotomies 
without diabetes and cirrhosis is similar to that of the general 
population(56,57).
There are no studies addressing precisely when to initiate 
phlebotomy sessions, but it is known that an earlier beginning 
is associated with a better survival(55,58). Currently, the threshold 
of serum ferritin used to start phlebotomies is taken as above 
normal range(50). After achieving a ferritin level of less than 50 
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economically viable, it is possible to consider that the diagnosis 
of non-HFE HH, or even the identification of combinations of 
mutations in the HJV, HAMP, TFR2, SLC40A1 and HFE genes, 
may become more common in the clinical practice.
Excluding HFE mutations and secondary iron overload 
are crucial steps before considering the diagnosis of non-HFE 
HH. Thus, genetic testing can lead to more adequate and faster 
therapeutic management.
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